Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
18,368 total articles
Enphase Energy announced an integration between its IQ Batteries and Evergen's advanced virtual power plant (VPP) orchestration platform, enhancing Australian homeowners' ability to optimize battery use, participate in grid-support programs, and benefit from various state and federal incentives. This collaboration aims to accelerate battery adoptio…
IP Strategy Holdings, Inc. unveiled the Story Global Wallet, a new interface designed to simplify access and interaction with the Story Protocol blockchain ecosystem. The wallet integrates seamlessly with popular wallets like MetaMask and Coinbase Wallet to streamline developer integration and user onboarding. This innovation aims to accelerate ado…
OPKO Health’s subsidiary, ModeX Therapeutics, has begun dosing patients in a Phase 1 clinical trial for MDX2003, a first-in-class tetraspecific T-cell engager antibody designed to treat relapsed or refractory B-cell lymphoma. MDX2003 targets two tumor antigens (CD19 and CD20) along with T-cell activators (CD3 and CD28) to enhance the immune system’…
The Beauty Health Company announced a corporate rebrand to SkinHealth Systems Inc. with the aim of becoming a clinically driven, science-backed medical aesthetics company. The company will continue trading under the ticker SKIN and focus on growing its skin health ecosystem anchored by its flagship Hydrafacial device along with complementary offeri…
PMV Pharmaceuticals has appointed Laurie Stelzer as the new Chair of its Board, succeeding Dr. Rich Heyman, effective after the 2026 Annual Meeting. This leadership transition coincides with the continuation of the PYNNACLE Phase 2 clinical trial of rezatapopt for TP53 Y220C mutated advanced solid tumors, with a planned NDA submission in early 2027…
Madrigal Pharmaceuticals announced it will release its first-quarter 2026 financial results on May 6, 2026, before the US financial market opens. The company will host a live webcast to discuss the financial and operating results. Madrigal is focused on developing therapies for metabolic dysfunction-associated steatohepatitis (MASH), including the …
Arteris, Inc., a semiconductor technology company specializing in network-on-chip interconnect IP and SoC software, announced it will release its financial results for Q1 2026 after market close on May 12, 2026, followed by a management conference call and webcast.
Red Violet, Inc., a provider of analytics and identity intelligence solutions, announced it will report its first quarter 2026 financial results after market close on May 6, 2026. The company will hold an earnings call to discuss the results and provide a business update.
Stereotaxis announced successful completion of the first US procedures using its MAGiC robotically-navigated magnetic cardiac ablation catheter, recently approved by the FDA. The MAGiC catheter is designed to treat arrhythmias in patients with complex congenital heart abnormalities, improving precision and outcomes where manual catheters failed. Th…
BridgeBio Pharma announced the approval and issuance of restricted stock unit grants to 33 new employees totaling 67,247 shares, as inducements for employment under Nasdaq Listing Rule 5635(c)(4), with vesting schedules tied to continued employment. The grants aim to attract and retain talent to support the company's focus on developing medicines f…
Stock Yards Bancorp, Inc. (NASDAQ: SYBT) reported strong first quarter 2026 earnings of $36.6 million, or $1.24 per diluted share, representing growth from $33.3 million, or $1.13 per diluted share, in Q1 2025. The performance was driven by solid loan growth across markets, net interest margin expansion, and record wealth management revenue. The co…
Arq, Inc., a U.S. producer of activated carbon and environmentally efficient carbon products, announced it will release its first quarter 2026 financial results on May 6, followed by an earnings conference call on May 7. The company is the only vertically integrated activated carbon producer in North America, focusing on environmental technology so…
Zevra Therapeutics, a commercial-stage biopharmaceutical company specializing in rare disease therapies, announced it will release its corporate and financial results for Q1 2026 on May 6, 2026, after market close. The company will also host a conference call and webcast to discuss these results. Zevra continues to focus on expanding its geographic…
ASML Holding N.V. disclosed the results of its 2026 AGM, approving the 2025 financial statements, a final dividend payment leading to a total dividend of €7.50 per ordinary share for 2025, reappointments and appointments to the Board of Management and Supervisory Board, and authorizations for share issuance and repurchase programs. The AGM also cov…
Viomi Technology Co., Ltd, a NASDAQ-listed Chinese company specializing in AI-powered home water purification solutions, announced the filing of its 2025 annual report (Form 20-F) with the U.S. Securities and Exchange Commission. The report highlights Viomi's innovative 'Equipment + Consumables' business model, advanced technology in intelligent wa…
WEBUY GLOBAL LTD. announced a record-breaking performance at the NATAS Fair March 2026, generating over US$3.34 million in travel bookings within three days, a 27% increase year-over-year. The success was driven by the company's proprietary AI-assisted sales tool, enhancing customer consultations, demand analysis, and sales conversion in a highly c…
RenX Enterprises Corp. expects to report first quarter 2026 revenue of over $3.5 million, marking sequential growth compared to Q4 2025. The growth is driven by stronger material sales at its Myakka City organic processing facility and increased logistics revenue from its Zimmer Equipment Inc. transportation operations. The company is progressing w…
TG Therapeutics has announced data presentations at the American Academy of Neurology 2026 Annual Meeting highlighting the clinical and real-world effectiveness, safety, and optimized dosing of BRIUMVI (ublituximab-xiiy) for relapsing multiple sclerosis (RMS). These data include findings from the Phase 4 ENABLE observational study and the ENHANCE d…
Repligen Corporation will release its financial results for the first quarter of 2026 on May 5, followed by a conference call to discuss business updates and quarterly performance. The company specializes in bioprocessing technologies and serves biopharmaceutical developers and CDMOs worldwide.
BullFrog AI Holdings, a Nasdaq-listed AI-driven biomedical technology company, announced it has regained compliance with Nasdaq's minimum stockholders' equity requirement through sales under its at-the-market and equity-line-of-credit facilities. The company highlighted a recent commercial agreement with a top 5 global pharmaceutical firm, extendin…
CervoMed presented new placebo-controlled MRI analyses at the 2026 AAN Annual Meeting demonstrating that neflamapimod increased basal forebrain volume and enhanced functional connectivity in patients with Dementia with Lewy Bodies (DLB). The data strengthens evidence that neflamapimod may target the underlying disease process in DLB, a progressive …
Alterity Therapeutics presented new analyses of its Phase 2 trial data for ATH434, demonstrating significant slowing of functional decline in patients with Multiple System Atrophy (MSA) using the novel MuSyCA composite scale. The data reinforce ATH434's potential as a disease-modifying treatment ahead of planned Phase 3 regulatory engagement.
Caliber is progressing its Hyatt Studios hotel development platform across three U.S. markets—Steamboat Springs, Colorado; Riverwalk/Scottsdale, Arizona; and Georgetown, Texas—with plans to open the first hotel in late 2027. The developments capitalize on constrained supply and strong extended-stay demand, leveraging Hyatt's brand and aiming to tra…
Balchem Corporation has released its 2025 Sustainability Report highlighting significant progress including surpassing its 2030 greenhouse gas reduction target early by achieving a 31% decrease in Scope 1 and 2 emissions, reducing water withdrawal by 16%, and reinforcing commitments to the UN Global Compact and Sustainable Development Goals. The co…
NovaBridge Biosciences announced the appointment of Mark Hagler as President and Chief Commercial Officer. Hagler brings over 25 years of commercial leadership experience in biopharma, particularly in oncology and ophthalmology, and will drive corporate strategy, clinical trial design, and business development. The appointment supports the advancem…
